secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001437749-23-035141
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech prices $4.5M registered direct offering and concurrent private placement
--------------------------------------------------------------------------------

- Gross proceeds ~$4.5M from sale of 7,044,836 shares/pre-funded warrants at effective price of $0.64 (institutional) and $0.69 (insiders).
- Concurrent private placement of warrants to purchase up to 14,089,672 common shares at $0.64, exercisable from stockholder approval, 5-year term.
- Expected closing December 26, 2023; Maxim Group LLC serves as placement agent with 7% fee.
- CEO, CFO, directors, and employees purchased 326,086 shares at $0.69 per unit, participating alongside institutional investor.
- Company also amended bylaws to change voting standard to majority of votes cast for most stockholder matters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923035141/0001437749-23-035141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923035141/mbrx20231220_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-035141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer